Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500
Debt
Debt-to-Equity Ratio1.77
Current Ratio2.53
Quick Ratio1.66
Price-To-Earnings
Trailing P/E Ratio34.37
Forward P/E Ratio27.67
P/E Growth2
Sales & Book Value
Annual Sales$1.19 billion
Price / Sales4.93
Cash Flow$3.1246 per share
Price / Cash21.34
Book Value$12.26 per share
Price / Book5.44
Profitability
EPS (Most Recent Fiscal Year)$1.94
Net Income$64.74 million
Net Margins5.39%
Return on Equity17.90%
Return on Assets6.14%
Miscellaneous
Employees4,400
Outstanding Shares87,880,000
Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions
What is Integra Lifesciences' stock symbol?
Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."
When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?
Integra Lifesciences's stock split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were issued to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.
How were Integra Lifesciences' earnings last quarter?
Integra Lifesciences Holdings Corp (NASDAQ:IART) released its quarterly earnings results on Wednesday, April, 25th. The life sciences company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.09. The life sciences company had revenue of $357.10 million for the quarter, compared to analysts' expectations of $349.15 million. Integra Lifesciences had a return on equity of 17.90% and a net margin of 5.39%. The business's quarterly revenue was up 38.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.39 earnings per share. View Integra Lifesciences' Earnings History.
When is Integra Lifesciences' next earnings date?
What guidance has Integra Lifesciences issued on next quarter's earnings?
Integra Lifesciences updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share (EPS) guidance of $2.34-2.42 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.33. The company issued revenue guidance of $1.47-1.49 billion, compared to the consensus revenue estimate of $1.48 billion.
What price target have analysts set for IART?
14 Wall Street analysts have issued 12-month price targets for Integra Lifesciences' shares. Their predictions range from $50.00 to $74.00. On average, they expect Integra Lifesciences' stock price to reach $60.00 in the next year. View Analyst Ratings for Integra Lifesciences.
What are Wall Street analysts saying about Integra Lifesciences stock?
Here are some recent quotes from research analysts about Integra Lifesciences stock:
- 1. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month price target of $59 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure." (6/12/2018)
- 2. According to Zacks Investment Research, "Integra LifeSciences exited first quarter 2018 on a solid note. The strong year-over-year increase in revenues was fueled by balanced growth across all business segments. Integra’s successful progress with its channel expansion strategy and Codman integration buoy optimism. Notably, last December, the company announced plans within Orthopedics and Tissue Technologies segment to expand its sales channel, improve focus and competitiveness and better align the company’s product portfolio with clinical customers. Moreover, the increase in year-over-year investments in research and development is encouraging. The company’s promising guidance also instills confidence in the stock. Over the past three months, Integra Lifesciences has outperformed the broader industry. However, significant gross margin contractions caused by escalating costs are concerns. Also, a tough competitive landscape adds to the company’s woes." (5/1/2018)
Who are some of Integra Lifesciences' key competitors?
Some companies that are related to Integra Lifesciences include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and Eyepoint Pharmaceuticals (EYPT).
Who are Integra Lifesciences' key executives?
Integra Lifesciences' management team includes the folowing people:
- Mr. Peter J. Arduini, Pres, CEO & Director (Age 53)
- Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 75)
- Mr. Glenn G. Coleman, Corp. VP & CFO (Age 50)
- Mr. Richard D. Gorelick, Corp. VP of Admin., Gen. Counsel & Sec. (Age 57)
- Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 55)
Has Integra Lifesciences been receiving favorable news coverage?
Media headlines about IART stock have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Integra Lifesciences earned a news impact score of 0.08 on Accern's scale. They also assigned media headlines about the life sciences company an impact score of 45.42 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Integra Lifesciences' major shareholders?
Integra Lifesciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.60%), Champlain Investment Partners LLC (6.11%), Dimensional Fund Advisors LP (1.84%), Fisher Asset Management LLC (1.21%), Northern Trust Corp (1.10%) and Wells Fargo & Company MN (1.07%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Donald E Morel Jr, Glenn Coleman, James M Sullivan, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Peter J Arduini, Raymond G Murphy, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.
Which major investors are selling Integra Lifesciences stock?
IART stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Massachusetts Financial Services Co. MA, Boston Partners, Sector Gamma AS, Royal Bank of Canada, Great Lakes Advisors LLC, State of Wisconsin Investment Board and Dimensional Fund Advisors LP. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard D Gorelick and Richard E Caruso. View Insider Buying and Selling for Integra Lifesciences.
Which major investors are buying Integra Lifesciences stock?
IART stock was bought by a variety of institutional investors in the last quarter, including Westwood Holdings Group Inc., Champlain Investment Partners LLC, BlackRock Inc., Natixis, Schwab Charles Investment Management Inc., The Manufacturers Life Insurance Company , OppenheimerFunds Inc. and Wesbanco Bank Inc.. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Donald E Morel Jr. View Insider Buying and Selling for Integra Lifesciences.
How do I buy shares of Integra Lifesciences?
Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Integra Lifesciences' stock price today?
One share of IART stock can currently be purchased for approximately $66.68.
How big of a company is Integra Lifesciences?
Integra Lifesciences has a market capitalization of $5.85 billion and generates $1.19 billion in revenue each year. The life sciences company earns $64.74 million in net income (profit) each year or $1.94 on an earnings per share basis. Integra Lifesciences employs 4,400 workers across the globe.
How can I contact Integra Lifesciences?
Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]
MarketBeat Community Rating for Integra Lifesciences (IART)
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
